BRANFORD, Conn. , Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business
BRANFORD, Conn. --(BUSINESS WIRE)--Oct. 29, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company will present at BIO-Europe 2024 in Stockholm, Sweden on Monday,
BRANFORD, Conn. --(BUSINESS WIRE)--Oct. 11, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company has been invited to present at the 2024 Maxim Healthcare Virtual
BRANFORD, Conn. --(BUSINESS WIRE)--Sep. 24, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the upcoming late-breaking presentation related to ATR-04. The presentation by Dr.
BRANFORD, Conn. --(BUSINESS WIRE)--Sep. 18, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for
BRANFORD, Conn. --(BUSINESS WIRE)--Sep. 6, 2024-- Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill , COO, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference , being held
BRANFORD, Conn. --(BUSINESS WIRE)--Aug. 28, 2024-- Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome.
New investigational new drug (IND) application cleared to proceed by the US FDA for a Phase 1/2 clinical study of ATR-04 for moderate to severe EGFR inhibitor (“EGFRi”) associated dermal toxicity. There are an estimated 150,000 patients with EGFRi-associated skin rash in the US, representing a > $1
BRANFORD, Conn. --(BUSINESS WIRE)--Aug. 20, 2024-- Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome.
BRANFORD, Conn. --(BUSINESS WIRE)--Aug. 12, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024 , and provided a business